Business Standard

Tuesday, December 24, 2024 | 09:30 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Dexamethasone lowers deaths by one-third in severe Covid-19 patients: Study

The RECOVERY trial included over 11,500 patients, enrolled from more than 175 hospitals in the UK, noted a statement by the University of Oxford

drug, medicine, pharmaceutical, pharma
Premium

They found that dexamethasone reduced deaths by one-third in ventilated patients, and by one fifth in other patients receiving oxygen only.

Press Trust of India London
Low doses of the steroid dexamethasone can reduce deaths by one-third in ventilated Covid-19 patients, according to researchers who assessed the performance of the inexpensive drug in more than 2,100 patients.

The analysis is part of the RECOVERY (Randomised Evaluation of Covid-19 Therapy) trial which was established to test a range of potential therapies for Covid-19, including low-dose dexamethasone -- a steroid treatment.

The RECOVERY trial included over 11,500 patients, enrolled from more than 175 hospitals in the UK, noted a statement by the University of Oxford.

In the trial, a total of 2,104 patients were randomised to receive dexamethasone

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in